

Recall of Zofran and Entresto Packages

Novartis Pharmaceuticals Corporation ("Novartis"), in cooperation with the U.S. Consumer Product Safety Commission ("CPSC") and Food and Drug Administration ("FDA"), is voluntarily implementing a CPSC-approved corrective action plan for the following product packages distributed in the United States. This action is not a result of any quality or safety concerns with the medications for their intended use.

The blister cards in which these products are packaged are not child-resistant, posing a risk of harm if the tablets are swallowed by children. Products in bottles are NOT impacted.

Zofran ODT® 4mg and 8mg (ondansetron) Orally Disintegrating Tablets (ODT)

This notification applies ONLY to the NDCs and lot numbers below:

Product Description	Package Description	NDC Number on Carton	NDC Number on Blister Pack	Lot Number	Expiration Date
Zofran ODT 4 mg	Blister packs of 30 tablets	0078-0679-19	0078-0679-61	1657088	Dec 2019
Zofran ODT 8 mg	Blister packs of 30 tablets	0078-0680-19	0078-0680-61	1641546	Oct 2019

ENTRESTO® (sacubitril / valsartan) Tablets in 100 Count Hospital Unit Dose Blister Packages

This notification applies ONLY to the NDCs and lot numbers below:

Product Description	NDC Number on Carton	NDC Number on Blister Card	Lot Number	Expiration Date
Entresto FCT 24mg/26mg HUD	0078-0659-35	0078-0659-61	FX000005	Apr 2020
			FX000004	Apr 2020
			FX000003	Sep 2019
			F0010	Nov 2018
			F0009	Aug 2018
			F0007	Jul 2018
Entresto FCT 49mg/51mg HUD	0078-0777-35	0078-0777-61	FX000001	Dec 2019
			F0006	Oct 2019
			F0005	Aug 2019
			F0004	Oct 2018

Product Description	NDC Number on Carton	NDC Number on Blister Card	Lot Number	Expiration Date
Entresto FCT 97mg/103mg HUD	0078-0696-35	0078-0696-61	FX000002	Mar 2020
			F0007	Feb 2020
			F0006	Dec 2019
			F0005	Dec 2018
			F0004	Oct 2018

These blister packs were developed solely for use in institutions (i.e., hospitals). However, we learned that some of these institutional packs were sent to retail pharmacies, indicating that they may have been dispensed for in-home use.

REPRESENTATIVE PHOTOS:

These images show the type of packaging involved in the voluntary recall. Products in bottles are NOT impacted. NDC numbers, lot numbers and expiration dates in the following example images should be disregarded. They are NOT those involved in the recall. Please refer to the table of affected lots above.



Zofran ODT 4mg



Zofran ODT 4mg



Zofran ODT 8mg



Zofran ODT 8mg



Entresto FCT 24mg/26mg HUD



Entresto FCT 49mg/51mg HUD



Entresto FCT 97mg/103mg HUD

PATIENT ACTION:

Anyone having the packages listed above should call Novartis Pharmaceuticals Corporation at 888-NOW-NOVA (888-669-6682) from 8 a.m. to 8 p.m. ET Monday through Friday and 9 a.m. to 6 p.m. ET Saturday and Sunday to order a child-resistant pouch in which to store the blister packs within your possession.

The quality of these products has not been compromised, so patients should continue taking their medicine as directed by their physician. However, due to the risk of harm to children, immediately secure this medicine so that it is out of the sight and reach of children.

Instructions for using the child-resistant pouch are on the pouches themselves, and the following video demonstrates their use.


Further information about this recall is available by calling Novartis at 888-NOW-NOVA (888-669-6682).

To learn more about the Sandoz products affected by this recall and requiring corrective action, please click [here](#) to be redirected to the Sandoz website.

Any medical related inquiries should be directed to Novartis Pharmaceuticals Corporation at 888-NOW-NOVA (888-669-6682). Please report any adverse events by calling Novartis at the same phone number, or by e-mailing usdrugsafety.operations@novartis.com. Adverse events can also be reported to the FDA online at www.fda.gov/medwatch/report.htm.

Click the images below for the related retail posters:

SAFETY NOTICE
Zofran® ODT (ondansetron)
4 mg and 8 mg Orally Disintegrating Tablets (ODT)



Novartis Pharmaceuticals Corporation has determined that blister packs of Zofran ODT (ondansetron) 4 mg and 8 mg Orally Disintegrating Tablets (ODT) distributed in the U.S. are not child-resistant, posing a risk of harm if the tablets are swallowed by children.

These products are voluntarily recalled for corrective action because the blister packs are not child-resistant.

There are no quality or safety issues with the medication itself for its intended use.

This notification applies only to the following NDC numbers with corresponding lot numbers and expiration dates.

Product Description	NDC on Carton	NDC on Blister Pack	Lot Number	Expiry Date
Zofran ODT 4 mg	0078-0679-19	0078-0679-61	1657066	Dec 2019
Zofran ODT 8 mg	0078-0680-19	0078-0680-61	1641546	Oct 2019


What do patients need to do?

1. Immediately secure this medicine so that it is out of the sight and reach of children.
2. Continue taking your Zofran tablets as prescribed, as there are no safety or quality issues with the medicine itself.
3. Please contact Novartis Pharmaceuticals Corporation at **888-NOW-NOVA (888-669-6682)** for important information on corrective action for your Zofran blister packs.

We appreciate your immediate attention and cooperation and apologize for this situation.


Please report any adverse events by calling Novartis at 888-NOW-NOVA (888-669-6682) or by emailing usdrugsafety.operations@novartis.com. Adverse events can also be reported to FDA online at www.fda.gov/medwatch/report.htm.

Post until November 6, 2019
In cooperation with the U.S. Consumer Product Safety Commission



Zofran Retail Poster

SAFETY NOTICE
ENTRESTO® (sacubitril / valsartan) Tablets in Blister Packs



Novartis Pharmaceuticals Corporation has determined that the 100 count Hospital Unit Dose BLISTER PACKS of Entresto (sacubitril/valsartan) Tablets distributed in the U.S. are not child-resistant, posing a risk of harm if the tablets are swallowed by children.

These products are voluntarily recalled for corrective action because the blister packs are not child-resistant.

There are no quality or safety concerns with the medicines for their intended use.

Blister packs were intended for institutional (i.e., hospital) use only. A small number of blister packs may have been dispensed for in-home use in the U.S. market.

Entresto Tablets in bottles are not affected by this recall.

This notification applies ONLY to the NDC and lot numbers listed below.

Product Description	NDC Number on Carton	NDC Number on Blister Pack	Lot Number	Expiration Date
Entresto FCT 24 mg/26 mg HUD Blister Pack	0078-0659-35	0078-0659-61	F0000005 F0000004 F0000003 F0010 F0009 F0007	Apr 2020 Apr 2020 Sep 2019 Nov 2018 Aug 2018 Jul 2018
Entresto FCT 48 mg/51 mg HUD Blister Pack	0078-0777-35	0078-0777-61	F0000001 F0006 F0005 F0004	Dec 2019 Oct 2019 Aug 2019 Oct 2018
Entresto FCT 97 mg/103 mg HUD Blister Pack	0078-0596-35	0078-0596-61	F0000002 F0007 F0006 F0005 F0004	Mar 2020 Feb 2020 Dec 2019 Dec 2018 Oct 2018


What do patients need to do?

1. Immediately secure this medicine so that it is out of the sight and reach of children.
2. Continue taking your medicine as prescribed, as there are no safety or quality issues with the medicine itself.
3. Please contact Novartis Pharmaceutical Corporation at **888-NOW-NOVA (888-669-6682)** for important information on corrective action for your Entresto blister packs.

We appreciate your immediate attention and cooperation and apologize for this situation.

Please report any adverse events by calling Novartis at 888-NOW-NOVA (888-669-6682) or by emailing usdrugsafety.operations@novartis.com. Adverse events can also be reported to FDA online at www.fda.gov/medwatch/report.htm.

Post until November 6, 2019
In cooperation with the U.S. Consumer Product Safety Commission



Entresto Retail Poster

Source URL: <https://prod1.novartis.com/us-en/recall-zofran-and-entresto-packages>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/recall-zofran-and-entresto-packages>
2. <https://www.us.sandoz.com/patients-customers/product-safety-notice>
3. <mailto:usdrugsafety.operations@novartis.com>
4. <https://www.fda.gov/medwatch/report.htm>
5. https://prod1.novartis.com/us-en/sites/novartis_us/files/2022-03/ZOFRAN%20Recall%20Poster%20%287.4.18%29%20-%20FINAL_0.pdf
6. https://prod1.novartis.com/us-en/sites/novartis_us/files/2022-

